Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Usage of Antidepressants and Weight

항우울제의 사용과 체중

  • Lee, Ung (Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Cho, Sung Joon (Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 이웅 (성균관대학교 의과대학 강북삼성병원 정신건강의학교실) ;
  • 조성준 (성균관대학교 의과대학 강북삼성병원 정신건강의학교실)
  • Received : 2020.03.13
  • Accepted : 2020.07.13
  • Published : 2020.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Depressive disorder is a very common disease, clinical manifestations vary, and the mechanism is not clear. Therefore, a pharmacotherapy is very important to achieve sufficient therapeutic effect, but the choice of drug is not easy due to the occurrence of side effects of treatment and confusion with clinical features. It is easy to overlook the side effects of weight gain with antidepressants compared with antipsychotics, but they are frequently observed in clinical settings. The first-generation antidepressants have higher weight gains than selective serotonin reuptake inhibitors. Serotonin norepinephrine reuptake inhibitors are observed to have less weight gain, and dopamine norepinephrine reuptake inhibitors have weight loss effect due to decreased appetite. Mirtazapine, an atypical antidepressant, has a strong histamine H1 blockade, and gains weight gain from short-term use. The effects of desvenlafaxine, vortioxetine, and agomelatin on weight, which have recently been increasing in use, have not been largely identified. For better compliance, studies on weight gain due to the use of antidepressants are needed.

Keywords

Acknowledgement

The following institutions are joining: Kangbuk Samsung Hospital, Workplace Mental Health Institute.

References

  1. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3-21. https://doi.org/10.1002/mpr.138
  2. Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991.
  3. Cho MJ, Chang SM, Hahm BJ, Chung IW, Bae A, Lee YM, et al. Prevalence and correlates of major mental disorders among Korean adults: a 2006 National Epidemiologic Survey. J Korean Neuropsychiatr Assoc 2009;48:143-152.
  4. Korean Neuropsychiatric Association. Textbook of Neuropsychiatry. 3rd ed. Seoul: iMiS Company;2017.
  5. Song HR, LEE HY, Shim SH, Kwon YJ. Neuroinflammation and psychiatric illness. Korean J Biol Psychiatry 2016;23:12-17.
  6. Leonard BE. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:261-267. https://doi.org/10.1016/j.pnpbp.2013.10.018
  7. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23:1-21. https://doi.org/10.1037/a0038550
  8. Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 2015;20:1142-1150. https://doi.org/10.1038/mp.2015.92
  9. Weilburg JB. An overview of SSRI and SNRI therapies for depression. Manag Care 2004;13:25-33.
  10. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011;12:1623-1632. https://doi.org/10.1517/14656566.2011.585459
  11. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 18:4-11.
  12. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659. https://doi.org/10.1016/S0006-3223(03)00231-2
  13. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163:210-216. https://doi.org/10.1176/appi.ajp.163.2.210
  14. Bahk WM, Min KJ. Textbook of depressive disorders. Seoul: Sigma press;2012.
  15. Jeong HJ, Moon E. Novel pharmacological treatment for depression. Korean J Biol Psychiatry 2016;23:1-11
  16. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61Suppl 11:37-41.
  17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychaitric Association;2013.
  18. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012;35:1171-1180. https://doi.org/10.2337/dc11-2055
  19. Cho SJ, Lee HJ, Rhee SJ, Kim EY, Kim KN, Yoon DH, et al. The relationship between visceral adiposity and depressive symptoms in the general Korean population. J Affect Disord 2019;244:54-59. https://doi.org/10.1016/j.jad.2018.09.046
  20. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, National Heart L, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-e18.
  21. Assari S, Caldwell CH. Gender and Ethnic Differences in the association between obesity and depression among black adolescents. J Racial Ethn Health Disparities 2015;2:481-493. https://doi.org/10.1007/s40615-015-0096-9
  22. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, doubleblind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991;24:62-67. https://doi.org/10.1055/s-2007-1014440
  23. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170-1176.
  24. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643-658. https://doi.org/10.1016/S0149-2918(00)88317-4
  25. Moon CA, Jesinger DK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pract 1991;45:259-262.
  26. Shi Z, Atlantis E, Taylor AW, Gill TK, Price K, Appleton S, et al. SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles: results from a 4-year Australian follow-up study. BMJ Open 2017;7:e016224. https://doi.org/10.1136/bmjopen-2017-016224
  27. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000;61:863-867. https://doi.org/10.4088/JCP.v61n1109
  28. Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000;20:645-652. https://doi.org/10.1097/00004714-200012000-00010
  29. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999;60:22-28. https://doi.org/10.4088/JCP.v60n0105
  30. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ 2018;361:k1951. https://doi.org/10.1136/bmj.k1951
  31. Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52- week extension study. Int Clin Psychopharmacol 2014;29:36-44. https://doi.org/10.1097/YIC.0000000000000010
  32. Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010;12:e1-e8.
  33. Harto-Truax N, Stern WC, Miller LL, Sato TL, Cato AE. Effects of bupropion on body weight. J Clin Psychiatry 1983;44:183-186.
  34. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-196.
  35. Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:208-211. https://doi.org/10.1016/j.pnpbp.2010.11.006
  36. Lee J, Cho SJ, Lee KS, Yook K, Choe AY, Lee S, et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: a preliminary randomized placebo-controlled Trial. Clin Psychopharmacol Neurosci 2011;9:73-77. https://doi.org/10.9758/cpn.2011.9.2.73
  37. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998;13:63-73. https://doi.org/10.1097/00004850-199803000-00002
  38. Goodnick PJ, Kremer C, Wingard P. Weight change during mirtazapine therapy. Prim Psychiatry 1998;3:103-108.
  39. Caffey EM Jr, Rosenblum MP, Klett CJ. Side effects and laboratory findings in a study of anti-depressant drugs. Dis Nerv Syst 1962;23:444-449.
  40. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988;26:265-271. https://doi.org/10.1016/0165-1781(88)90120-5
  41. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988;8:323-330.
  42. Frank E, Kupfer DJ, Bulik CM, Levenson JA. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990;20:165-172. https://doi.org/10.1016/0165-0327(90)90140-4
  43. Frank E, Kupfer DJ, Buhari A, McEachran AB, Grochocinski VJ. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord 1992;26:65-72. https://doi.org/10.1016/0165-0327(92)90036-6
  44. Feiger AD, Bielski RJ, Bremner J, Heiser JF, Trivedi M, Wilcox CS, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999;14:19-28. https://doi.org/10.1097/00004850-199901000-00002
  45. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychiatr Ann 1999;29:580-594. https://doi.org/10.3928/0048-5713-19991001-08
  46. Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013:CD008851.
  47. Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord 1984;7:133-138. https://doi.org/10.1016/0165-0327(84)90031-4
  48. Benazzi F. Weight gain in depression remitted with antidepressants: pharmacological or recovery effect? Psychother Psychosom 1998;67:271-274. https://doi.org/10.1159/000012291
  49. Fernstrom MH, Kupfer DJ. Imipramine treatment and preference for sweets. Appetite 1988;10:149-155. https://doi.org/10.1016/0195-6663(88)90066-9
  50. Levitt AJ, Joffe RT, Esche I, Sherret D. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987;48:27-28.
  51. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996;11:273-278. https://doi.org/10.1097/00004850-199612000-00009
  52. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 1995;351:357-373. https://doi.org/10.1002/cne.903510304
  53. Hoffman BJ, Mezey E. Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett 1989;247:453-462. https://doi.org/10.1016/0014-5793(89)81390-0
  54. Britton DR, Koob GF, Rivier J, Vale W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 1982;31:363-367. https://doi.org/10.1016/0024-3205(82)90416-7
  55. Levine AS, Rogers B, Kneip J, Grace M, Morley JE. Effect of centrally administered corticotropin releasing factor (CRF) on multiple feeding paradigms. Neuropharmacology 1983;22:337-339. https://doi.org/10.1016/0028-3908(83)90249-6
  56. Pijl H, Koppeschaar HP, Willekens FL, Op de Kamp I, Veldhuis HD, Meinders AE. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 1991;15:237-242.
  57. Fernstrom MH. Depression, antidepressants, and body weight change. Ann N Y Acad Sci 1989;575:31-39. https://doi.org/10.1111/j.1749-6632.1989.tb53229.x